Articles with public access mandates - Bjoern PapkeLearn more
Available somewhere: 13
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
KL Bryant, CA Stalnecker, D Zeitouni, JE Klomp, S Peng, AP Tikunov, ...
Nature medicine 25 (4), 628-640, 2019
Mandates: US Department of Defense, US National Institutes of Health, German Research …
Drugging RAS: Know the enemy
B Papke, CJ Der
Science 355 (6330), 1158-1163, 2017
Mandates: US Department of Defense, US National Institutes of Health, German Research …
KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transport
M Schmick, N Vartak, B Papke, M Kovacevic, DC Truxius, L Rossmannek, ...
Cell 157 (2), 459-471, 2014
Mandates: US National Institutes of Health, German Research Foundation
Identification of pyrazolopyridazinones as PDEδ inhibitors
B Papke, S Murarka, HA Vogel, P Martín-Gago, M Kovacevic, DC Truxius, ...
Nature communications 7 (1), 11360, 2016
Mandates: German Research Foundation, Cancer Research UK, European Commission
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
GA Hobbs, NM Baker, AM Miermont, RD Thurman, M Pierobon, TH Tran, ...
Cancer discovery 10 (1), 104-123, 2020
Mandates: US Department of Defense, US National Institutes of Health, German Research …
Low-dose vertical inhibition of the RAF-MEK-ERK cascade causes apoptotic death of KRAS mutant cancers
I Ozkan-Dagliyan, JN Diehl, SD George, A Schaefer, B Papke, ...
Cell reports 31 (11), 2020
Mandates: US Department of Defense, US National Institutes of Health, German Research …
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer
CM Goodwin, AM Waters, JE Klomp, S Javaid, KL Bryant, CA Stalnecker, ...
Cancer research 83 (1), 141-157, 2023
Mandates: US Department of Defense, US National Institutes of Health, German Research …
Concurrent inhibition of IGF1R and ERK increases pancreatic cancer sensitivity to autophagy inhibitors
CA Stalnecker, KR Grover, AC Edwards, MF Coleman, R Yang, ...
Cancer research 82 (4), 586-598, 2022
Mandates: US Department of Defense, US National Institutes of Health, German Research …
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment
JE Klomp, YS Lee, CM Goodwin, B Papke, JA Klomp, AM Waters, ...
Cell reports 37 (9), 2021
Mandates: US Department of Defense, US National Institutes of Health, German Research …
The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer
JN Diehl, JE Klomp, KR Snare, PS Hibshman, DR Blake, ZD Kaiser, ...
Journal of Biological Chemistry 297 (5), 2021
Mandates: US Department of Defense, US National Institutes of Health, Pancreatic …
Targeting p130Cas-and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition
AM Waters, TO Khatib, B Papke, CM Goodwin, GA Hobbs, JN Diehl, ...
Cell reports 35 (13), 2021
Mandates: US Department of Defense, US National Institutes of Health, German Research …
Silencing of oncogenic KRAS by mutant-selective small interfering RNA
B Papke, SH Azam, AY Feng, C Gutierrez-Ford, H Huggins, PS Pallan, ...
ACS Pharmacology & Translational Science 4 (2), 703-712, 2021
Mandates: US Department of Defense, US National Institutes of Health, German Research …
Defining the KRAS-regulated kinome in KRAS-mutant pancreatic cancer
JN Diehl, JE Klomp, KR Snare, DR Blake, PS Hibshman, ZD Kaiser, ...
bioRxiv, 2021.04. 27.441678, 2021
Mandates: US Department of Defense, US National Institutes of Health, Pancreatic …
Publication and funding information is determined automatically by a computer program